ReviewNature reviews. Cardiology2023
Hypertension in China: epidemiology and treatment initiatives.
Review in Nature reviews. Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 7 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Prevalence and treatment and control rates of hypertension among Chinese adults from 2016 to 2022: a meta-analysis.BMC public health · 2026Pooled it
- Risk factors for refracture after vertebral augmentation in postmenopausal women with osteoporotic vertebral compression fractures: a systematic review and meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Pooled it
- Hypertension-gut microbiota research trends: a bibliometric and visualization analysis (2000-2025).Frontiers in microbiology · 2025Pooled it
- A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients.Advances in therapy · 2024Pooled it
- Effect of soy isoflavone supplementation on blood pressure: a meta-analysis of randomized controlled trials.Nutrition journal · 2024Pooled it
- Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Wearable Devices as Tools for Better Hypertension Management in Elderly Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Trial
- Does an antihypertensive diet cost more? Analysis from the Chinese Heart-Healthy diet trial.Public health nutrition · 2024Trial
- Effects of the Chinese heart-healthy diet (Sichuan cuisine) on lowering blood pressure in adults with hypertension: a randomized controlled feeding trial.Asia Pacific journal of clinical nutrition · 2024Trial
- Article
- Blood pressure lowering efficacy of sacubitril/allisartan versus olmesartan in elderly Chinese hypertensive patients.Journal of geriatric cardiology : JGC · 2026Article
- Achieved home systolic blood pressure and cardiovascular risk in older hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Ambient Ultrafine Particles and Hypertensive Disorders of Pregnancy: A Mediation Analysis of Homocysteine in a Birth Cohort.Environment & health (Washington, D.C.) · 2026Article
- Ion-Driving Polymer Entanglement for Dynamic Organic Phosphorescence.Angewandte Chemie (International ed. in English) · 2026Article
- Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis.Cardiovascular diabetology · 2026Article
- Asian expert consensus on high-quality hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Lifetime health benefits, costs, and cost-effectiveness of salt substitution for stroke survivors in China: a microsimulation modeling study.The Lancet regional health. Western Pacific · 2026Article
- Within-visit and short- and long-term between-visit blood pressure variability as predictors of cardiovascular events and mortality in elderly Chinese.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- A multi-layer retrieval-augmented large language model framework for enhancing hypertension education.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past two to three decades have seen a steady increase in the prevalence of hypertension in China, largely owing to increased life expectancy and lifestyle changes (particularly among individuals aged 35-44 years). Data from the China hypertension survey conducted in 2012-2015 revealed a high prevalence of grade 3 hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg) in the general population, which increased with age to up to 5% among individuals aged ≥65 years. The risk profile of patients with hypertension in China has also been a subject of intense study in the past 30 years. Dietary sodium and potassium intake have remained largely the same in China in the past three decades, and salt substitution strategies seem to be effective in reducing blood pressure levels and the risk of cardiovascular events and death. However, the number of individuals with risk factors for hypertension and cardiovascular disease in general, such as physical inactivity and obesity, has increased dramatically in the same period. Moreover, even in patients diagnosed with hypertension, their disease is often poorly managed owing to a lack of patient education and poor treatment compliance. In this Review, we summarize the latest epidemiological data on hypertension in China, discuss the risk factors for hypertension that are specific to this population, and describe several ongoing nationwide hypertension control initiatives that target these risk factors, especially in the low-resource rural setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.